AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Sodium channel protein type 4 subunit alpha

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries for ion channels.

 Fig. 1. The sreening workflow of Receptor.AI

It features detailed molecular simulations of the ion channel in its native membrane environment across its open, closed, and inactivated forms, coupled with ensemble virtual screening considering conformational mobility in these states. Potential binding sites are explored within the pore, in the gating region, and at allosteric locations to encompass all potential mechanisms of action.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P35499

UPID:

SCN4A_HUMAN

Alternative names:

SkM1; Sodium channel protein skeletal muscle subunit alpha; Sodium channel protein type IV subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.4

Alternative UPACC:

P35499; Q15478; Q16447; Q7Z6B1

Background:

The Sodium channel protein type 4 subunit alpha, also known as Nav1.4, is a critical component of the voltage-gated sodium channel complex. This protein facilitates the passage of Na(+) ions, essential for muscle fiber excitability and the contraction-relaxation cycles in skeletal muscles. Its alternative names include SkM1, Sodium channel protein skeletal muscle subunit alpha, and Voltage-gated sodium channel subunit alpha Nav1.4.

Therapeutic significance:

Nav1.4 is implicated in several neuromuscular disorders, such as Paramyotonia congenita of von Eulenburg, Hypokalemic and Hyperkalemic periodic paralysis, and Myotonia SCN4A-related. These conditions highlight the protein's pivotal role in muscle function and underscore the potential for targeted therapies to correct its dysregulation.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.